|
Medtronic submits this report to comply with fda regulations 21 cfr parts 4 and 803.Medtronic has made reasonable efforts to provide as much relevant information as is available to the company as of the submission date of this report.This report does not constitute an admission or a conclusion by fda, medtronic, or its employees that the device, medtronic, or its employee caused or contributed to the event described in the report.Any required fields that are unpopulated are blank because the information is currently unknown or unavailable.Medtronic will submit a supplemental report if additional relevant information becomes known.
|
|
The patient¿s attorney alleged a deficiency against the device.The product was used for therapeutic treatment of a ventral hernia.It was reported that after the implant, the patient experienced drainage from wound, wound infection, necrosis, fistula, inflammatory rind, scar tissue.Post-operative patient treatment included ct scan, incision, drainage of abdominal wall wound, debridement of skin, soft tissue, complex wound closure of abdominal wall, removal of suture, abdominal wall wound closure.
|